BioNTech Investor Day Presentation Deck

BNT211: Phase 1/2 trial evaluating next-generation CAR T targeting claudin-6 with CARVac in solid tumors CAR T-cell therapy + CARVac RNA vaccine to amplify CAR T cells in vivo Claudin-6 not present in healthy tissues 2nd generation CAR directed against CLDN6, a cancer specific carcino-embryonic antigen CLDN6 is expressed in multiple solid cancers with high medical need CARVac drives in vivo expansion, persistence and efficacy of CAR T Intracellular Extracellular aC LDN6 scFv CD8 hinge 4-1BB CD32 ● Relapsed/Refractory advanced solid tumors CLDN6-positive: ≥50% of tumor cells CLDN6-high [II/II||+] CLDN6, claudin 6; E15, embryonic day 15; EL, extracellular loop; PO, at birth. Reinhard K, et al. Science 2020; 367:446-453. Phase 1 - Dose escalation Monotherapy CLDN6 CAR T cells (3 DLs) Expressed in various cancers Combination CLDN6 CAR T cells (3 DLs) + CLDN6-encoding CARVac Ovarian Phase 2 trial planned for 2023 EMA PRIME designation in testicular cancer RP2D Testicular Lung F Cell therapies Phase 2 - Dose expansion Testicular cancer Ovarian cancer Endometrial cancer Lung cancer Gastric cancer Tumors not otherwise specified BIONTECH 133

View entire presentation